Simmons & Simmons LLP (Munich)

The present disclosure is to provide an injection molding machine and the like that allows the user to easily grasp interlock information related to cores. An injection molding machine (1), includes: an injection device (3) melting and injecting an injection material; a mold clamping device (4) clamping a metal mold (41) with a core (47) that is injected with the injection material; a control device (2) controlling an action of the core (47); and a display unit (24) displaying an action status of the core (47), and the display unit (24) includes a core action icon (71) indicative of an action of the core (47), and a first information icon (74) indicative of interlock information concerning the core (47), and the core action icon (71) and the first information icon (74) are displayed in association with each other.

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.

A vehicle (100) on which an autonomous driving kit (ADK) (200) is mountable comprises a control system (120) configured to control a plurality of functions of the vehicle (100) and a vehicle control interface box (VCIB) (110) configured to mediate communication of a signal between the ADK (200) and the control system (120). The ADK (200) is configured to operate in one control mode selected from a plurality of types of control modes. The VCIB (110) is configured to receive from the ADK (200) and store function setting information for each of the plurality of types of control modes. The function setting information is information indicating whether each of the plurality of functions is enabled or disabled. The VCIB (110) is configured to request the control system (120) to enable or disable each of the plurality of functions based on the function setting information corresponding to the selected one control mode.

The present disclosure relates to dosing regimens of pharmaceutical compositions of anti-CD40 antibodies, such as humanized anti-CD40 antibodies, and uses thereof in the treatment of rheumatoid arthritis.

An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage.The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.

The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.GS) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).

Die vorliegende Erfindung betrifft einen Transportbehälter (1) mit Behälterrahmen (2) und Behälterboden (3), wobei der Behälterrahmen (2) und der Behälterboden (3) einen Behälterinnenraum (4) festlegen, wobei der Behälterrahmen (2) Seitenwände (21, 22) des Transportbehälters (1) ausbildet, von denen mindestens zwei gegenüberliegende Seitenwände (21, 22) mit einem Tragegriff (5, 6) und mit einem daran angrenzenden Durchgriffsloch (7, 8) versehen sind, und wobei der Tragegriff (5, 6) zumindest an seiner zum Behälterinnenraum (4) weisenden Seitenfläche (5a; 6a) eine Vielzahl an Vertiefungen (51; 61) aufweist, die zumindest vier sechs- oder mehreckige Hohlräume (51a; 61a) umfasst, deren jeweilige Innenoberfläche zumindest teilweise eine Kugelsegmentform ausbildet. Ferner betrifft die vorliegende Erfindung ein entsprechendes Spritzgussverfahren sowie ein entsprechendes Spritzgusswerkzeug.

Disclosed are novel methods for making compositions which contain selected organic-inorganic dispersions and a silica sol and the use of these compositions in coatings.

An injection molding machine heats an injection nozzle using, as a target temperature, a detected temperature of a synchronization zone (step S6), when a detected temperature of the injection nozzle is lower than a nozzle reference temperature (YES in step S2). The injection molding machine heats the injection nozzle using a nozzle set temperature as a target temperature, when a detected temperature of the injection nozzle is higher than the nozzle reference temperature (NO in step S2).

Zusammenfassung wird geladen …